Colorectal Cancer Therapeutics Market
完整報告名稱與涵蓋範圍
Colorectal Cancer Therapeutics Market Size, Share & Trends Analysis Report, By Drug Class (Chemotherapy Regimens, Anti-EGFR and Anti-VEGF Antibodies, Targeted Therapies (BRAF, KRAS G12C, HER2), Immune Checkpoint Inhibitors, Antibody-Drug Conjugates and Emerging Modalities), By Disease Stage (Adjuvant and Early-Stage Disease, Metastatic First-Line, Metastatic Later-Line), By Biomarker Segment (RAS Wild-Type, RAS/BRAF Mutant, MSI-High and dMMR, HER2-Positive and Other Biomarkers), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The colorectal cancer therapeutics market covers systemic anticancer drugs used across adjuvant, first-line metastatic and later-line settings, including chemotherapy backbones, anti-EGFR and anti-VEGF antibodies, biomarker-directed targeted therapies, immune checkpoint inhibitors and emerging antibody-drug conjugates and bispecifics. Surgery, radiotherapy, screening and diagnostic testing are excluded, though biomarker testing rates are modelled as adoption drivers.
Treatment has fragmented into biomarker-defined subsets: KRAS G12C and BRAF V600E inhibitors, HER2-directed regimens, immunotherapy for MSI-high disease and anti-EGFR therapy for RAS wild-type left-sided tumors have each carved out populations, while later-line options such as trifluridine-tipiracil combinations and multikinase inhibitors extend survival. The pipeline is focused on KRAS G12D and pan-RAS inhibitors, immunotherapy for microsatellite-stable tumors, ADCs and circulating tumor DNA-guided adjuvant strategies that could shift treatment earlier and expand durations. Rising incidence in adults under fifty and expanding screening in Asia add to the treated population.
North America, Europe and Japan generate most revenue, and China is the largest source of incremental patients and of domestic innovator drugs. Competition brings together large oncology franchises, targeted-therapy specialists and Asian pharmaceutical groups with region-specific approvals.
The InsightAce study provides US$ revenue forecasts for every drug class, disease stage, biomarker segment and distribution channel and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Colorectal Cancer Therapeutics Market Snapshot
Chapter 4. Global Colorectal Cancer Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. Drug Class & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Drug Class:
5.2.1. Chemotherapy Regimens
5.2.2. Anti-EGFR and Anti-VEGF Antibodies
5.2.3. Targeted Therapies (BRAF, KRAS G12C, HER2)
5.2.4. Immune Checkpoint Inhibitors
5.2.5. Antibody-Drug Conjugates and Emerging Modalities
Chapter 6. Market Segmentation 2: By Disease Stage Estimates & Trend Analysis
6.1. Disease Stage & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Disease Stage:
6.2.1. Adjuvant and Early-Stage Disease
6.2.2. Metastatic First-Line
6.2.3. Metastatic Later-Line
Chapter 7. Market Segmentation 3: By Biomarker Segment Estimates & Trend Analysis
7.1. Biomarker Segment & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Biomarker Segment:
7.2.1. RAS Wild-Type
7.2.2. RAS/BRAF Mutant
7.2.3. MSI-High and dMMR
7.2.4. HER2-Positive and Other Biomarkers
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Specialty and Retail Pharmacies
Chapter 9. Colorectal Cancer Therapeutics Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Amgen Inc.
11.2. Merck & Co., Inc.
11.3. Bristol Myers Squibb
11.4. Roche Holding AG
11.5. Pfizer Inc.
11.6. Bayer AG
11.7. Eli Lilly and Company
11.8. Taiho Pharmaceutical Co., Ltd.
11.9. Takeda Pharmaceutical Company Limited
11.10. Merck KGaA
11.11. Daiichi Sankyo Company, Limited
11.12. Mirati Therapeutics (Bristol Myers Squibb)
11.13. Hutchmed (China) Limited
11.14. Jazz Pharmaceuticals plc
11.15. Seagen (Pfizer)
圖表清單 List of Tables & Figures
Table 1. Global Colorectal Cancer Therapeutics Market Revenue Forecast by Drug Class, 2026-2035 (US$ Mn)
Figure 1. Global Colorectal Cancer Therapeutics Market Segmentation and Scope Overview
Table 2. Global Colorectal Cancer Therapeutics Market Revenue Forecast by Disease Stage, 2026-2035 (US$ Mn)
Figure 2. Global Colorectal Cancer Therapeutics Market Share by Drug Class, 2026 & 2035
Table 3. Global Colorectal Cancer Therapeutics Market Revenue Forecast by Biomarker Segment, 2026-2035 (US$ Mn)
Figure 3. Biomarker-Defined Treatment Landscape in Metastatic Colorectal Cancer
Table 4. Global Colorectal Cancer Therapeutics Market Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Colorectal Cancer Pipeline by Target, Modality and Phase, 2026
Table 5. Global Colorectal Cancer Therapeutics Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Colorectal Cancer Therapeutics Growth Opportunity Analysis
Table 6. North America Colorectal Cancer Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Colorectal Cancer Therapeutics Market Participants
Table 7. Europe Colorectal Cancer Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Colorectal Cancer Therapeutics Market
Table 8. Asia Pacific Colorectal Cancer Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Early-Onset Incidence and Screening Expansion Effects on Treated Population, 2026-2035
Table 9. Strategic Developments of Leading Colorectal Cancer Therapeutics Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們